title: Stable overexpression of DNA fragmentation factor in T-47D cells: sensitization of breast cancer cells to apoptosis in response to acetazolamide and sulfabenzamide.
abstract: Alterations in expression of the DFF40 gene have been reported in some cancers. This study is an in vitro study of the therapeutic effects of gene transfer that lead to elevation in DFF40 expression within T-47D cells in the presence of sulfonamide drugs. In this study, we have constructed a eukaryotic expression vector for DFF40 and transfected it into T-47D cancer cells. We used real time RT-PCR to detect the expression of DFF40 and the MTT assay to determine effects of the sulfonamide drugs acetazolamide, sulfabenzamide, sulfathiazole and sulfacetamide on cell viability in the presence of increased and normal DFF40 levels. Cell cycle distribution was assessed by propidium iodide (PI) staining and the rates of apoptosis by annexin V/PI staining. The DNA laddering analysis was employed to evaluate apoptosis. We observed that overexpression of DFF40 was only effective in decreasing viability in cells incubated with acetazolamide and sulfabenzamide. There was enhanced apoptosis in these groups, particularly with acetazolamide. The cell cycle distribution analysis showed that in the presence of sulfonamide drugs there were no substantial changes in empty-vector or DFF40-transfected cells, except for those cells treated with sulfabenzamide or sulfathiazole. There was no DNA laddering in cells that expressed the empty vector when incubated with sulfonamide drugs. In contrast, we observed DNA laddering in cells that expressed DFF40 in the presence of acetazolamide. Our results have demonstrated that combinatorial use of some sulfonamides such as acetazolamide along with increased expression of DFF40 can potently kill tumor cells via apoptosis and may be beneficial for treatment of some chemoresistant cancers.
authors.affiliation: Department of Cell and Molecular Biology, School of Biology, College of Science, University of Tehran, Tehran, Iran.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Bagheri
authors.forename: Shahrokh
authors.initials: S
authors.lastname: Safarian
authors.forename: Mohamadreza Baghaban
authors.initials: MB
authors.lastname: Eslaminejad
authors.forename: Nader
authors.initials: N
authors.lastname: Sheibani
mesh_terms: D000086:Acetazolamide / Q000494:pharmacology*; D017304:Annexin A5; D017209:Apoptosis / Q000187:drug effects* / Q000502:physiology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D018076:DNA, Complementary / Q000235:genetics; D003851:Deoxyribonucleases / Q000378:metabolism*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects*; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D000075223:Poly-ADP-Ribose Binding Proteins; D011419:Propidium; D013449:Sulfonamides / Q000494:pharmacology
chemical_list: D017304:Annexin A5; D018076:DNA, Complementary; D000075223:Poly-ADP-Ribose Binding Proteins; D013449:Sulfonamides; D011419:Propidium; C113696:DFFB protein, human; D003851:Deoxyribonucleases; C034094:sulfabenzamide; D000086:Acetazolamide
references.citation: Br J Cancer. 2003 Jan 27;88(2):210-6
references.pmid: 12610505
references.citation: Int J Pharm. 2002 Nov 6;248(1-2):1-14
references.pmid: 12429455
references.citation: J Biol Chem. 1999 May 14;274(20):13836-40
references.pmid: 10318789
references.citation: Invest New Drugs. 2001;19(3):219-27
references.pmid: 11561678
references.citation: Cell Biol Int. 2014 Feb;38(2):228-38
references.pmid: 24155029
references.citation: Annu Rev Pharmacol Toxicol. 1976;16:309-27
references.pmid: 59572
references.citation: Biochem Biophys Res Commun. 2004 Jun 4;318(3):710-3
references.pmid: 15144896
references.citation: Ann Pharmacother. 1996 May;30(5):514-9
references.pmid: 8740334
references.citation: Acta Pharmacol Sin. 2002 Aug;23(8):745-51
references.pmid: 12147198
references.citation: Nature. 1998 Jan 1;391(6662):43-50
references.pmid: 9422506
references.citation: Cancer Res. 2002 Nov 1;62(21):6116-23
references.pmid: 12414636
references.citation: Nature. 1998 Jan 1;391(6662):96-9
references.pmid: 9422513
references.citation: Vet Res. 1993;24(4):316-26
references.pmid: 8220499
references.citation: Cell Death Differ. 2009 Jan;16(1):3-11
references.pmid: 18846107
references.citation: Oncogene. 2005 Sep 29;24(43):6584-9
references.pmid: 16007181
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4
references.pmid: 10688890
references.citation: Nat Rev Cancer. 2002 Apr;2(4):277-88
references.pmid: 12001989
references.citation: Oral Oncol. 2004 Apr;40(4):390-9
references.pmid: 14969818
references.citation: Eur J Biochem. 1968 Feb;3(4):453-60
references.pmid: 4966764
references.citation: J Med Chem. 1999 Sep 23;42(19):3789-99
references.pmid: 10508428
references.citation: J Pharm Sci. 1968 Sep;57(9):1455-78
references.pmid: 4877188
references.citation: J Pharmacol Exp Ther. 2007 Oct;323(1):398-405
references.pmid: 17660383
references.citation: Curr Med Chem. 2008;15(4):368-73
references.pmid: 18288991
references.citation: Nat Struct Biol. 2000 Aug;7(8):658-62
references.pmid: 10932250
references.citation: J Soc Biol. 2007;201(2):121-5
references.pmid: 17978743
references.citation: Acta Neurol Scand. 2007 Nov;116(5):322-7
references.pmid: 17922725
references.citation: Cancer Res. 2003 Oct 15;63(20):6942-7
references.pmid: 14583495
references.citation: Cell Biol Int. 2013 Apr;37(4):348-58
references.pmid: 23450781
references.citation: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6051-5
references.pmid: 11371636
references.citation: Med Res Rev. 2003 Sep;23(5):535-58
references.pmid: 12789686
references.citation: J Appl Physiol (1985). 2007 Apr;102(4):1313-22
references.pmid: 17023566
references.citation: Cell. 1997 Apr 18;89(2):175-84
references.pmid: 9108473
references.citation: BMJ. 2012 Oct 31;345:e7077
references.pmid: 23114063